EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Extended‐release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review

Amelia Woods iD, Catherine Foley iD, Katherine M Conigrave iD, Winifred Asare-Doku iD, Anthony Shakeshaft iD, Stella Settumba-Stolk iD, Michael Farrell iD, Michael Doyle iD

Addiction · 2025-05 · 120 (5) · 835-859

DOI: 10.1111/add.16766 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Addiction, online erschienen am 30.01.2025. Verfasst von Amelia Woods und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Randwick, Australia. Hauptthemen laut MEDLINE: Naltrexone, Buprenorphine, Prisoners, Narcotic Antagonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Drug and Alcohol Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Substance use (SU) is prevalent among individuals in the criminal justice system (CJS). However, there is often poor access to treatment. We aimed to assess the effectiveness of two medications, extended‐release naltrexone (XR‐NTX) and extended‐release buprenorphine (XR‐BUP) for the prison population.

Methods

We searched Scopus, OVID/Embase, PubMed/Medline, ProQuest, EBSCO, Cochrane Library and Australian Criminology Database for original articles published from 1 January 2002 to 31 December 2022. Inclusion criteria: 18+, substance use disorder; XR treatment; recent incarceration. We extracted study, participants, treatment characteristics and outcome variables. We conducted risk of bias assessments using the RoB‐2, ROBINS‐I, JBI tools and Evers et al.

Results

We identified 25 papers (16 studies) examining 3403 participants. Sixteen papers (9 studies) focused on XR‐NTX, eight (7 studies) on XR‐BUP and one on both. Eighteen papers (11 studies) were from the US, with the remainder from Norway, Australia, UK, Canada and Germany. There were eight RCTs (10 papers), four secondary observational analyses, four cohort studies, four economic analyses, two case series and one qualitative paper. Most studies had small–moderate samples, with varying retention and follow‐up periods. Among RCTs, two XR‐NTX studies for opioid use found no difference in retention vs treatment as usual and placebo, while one reported improved retention for XR‐NTX implant vs methadone. One RCT showed mixed retention results for XR‐NTX vs placebo in alcohol use. One XR‐BUP study showed improved or equivalent treatment retention (depending on measures) vs sublingual buprenorphine. There was no difference in overdoses. SU for XR‐NTX was challenging to assess due to differing definitions, measures and comparators. XR‐BUP yielded mixed SU results, with one indicating a greater effect and another no difference from comparators.

Conclusions

There is no clear evidence for the effectiveness of extended release naltrexone and buprenorphine among individuals in the criminal justice system compared with shorter acting formulations. But there is growing evidence for the effectiveness of extended release buprenorphine in reducing opioid use and improving treatment retention in that population, with potential cost offsets from initial medication expenses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneBuprenorphinePrisonersNarcotic AntagonistsSubstance-Related DisordersOpiate Substitution TreatmentHumansDelayed-Action PreparationsOpioid-Related Disorders

Stichwörter der Autor:innen

addiction treatment in prisonsextended‐release pharmacotherapyincarcerated populationsmedication‐assisted treatmentprison health servicesprisoner rehabilitationsubstance abuse treatmentsubstance use disorders

Substanzen

NaltrexoneDelayed-Action PreparationsBuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Randwick, Australia.
  • Drug and Alcohol Services SA (DASSA), Stepney, South Australia, Australia.
  • Drug Health Service, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Central Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
  • Edith Collins Centre for Translational Research on Alcohol, Drugs and Toxicology, Sydney Local Health District, Camperdown, NSW, Australia.
  • Poche Centre for Indigenous Health, University of Queensland, Toowong, Queensland, Australia.

ORCID-Profile: Amelia Woods, Catherine Foley, Katherine M Conigrave, Winifred Asare-Doku, Anthony Shakeshaft, Stella Settumba-Stolk, Michael Farrell, Michael Doyle

Förderung

  • National Drug and Alcohol Research Centre

Zitieren

APA

Woods, A., Foley, C., Conigrave, K. M., Asare-Doku, W., Shakeshaft, A., Settumba-Stolk, S., Farrell, M., & Doyle, M. (2025). Extended‐release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review. Addiction, 120(5), 835-859. https://doi.org/10.1111/add.16766

Vancouver

Woods A, Foley C, Conigrave KM, Asare-Doku W, Shakeshaft A, Settumba-Stolk S, et al. Extended‐release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review. Addiction. 2025;120(5):835-859. doi:10.1111/add.16766

BibTeX
@article{Woods2025,
  author = {Woods, Amelia and Foley, Catherine and Conigrave, Katherine M and Asare-Doku, Winifred and Shakeshaft, Anthony and Settumba-Stolk, Stella and Farrell, Michael and Doyle, Michael},
  title = {Extended‐release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review},
  journal = {Addiction},
  year = {2025},
  volume = {120},
  number = {5},
  pages = {835--859},
  doi = {10.1111/add.16766}
}
Kostenlos starten →